Novo Nordisk

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsvaerd, Denmark, with production facilities in eight countries and branches or offices in five countries.

The focus of Novo is on major chronic diseases, which affect hundreds of millions of people and are among the world's most pressing health issues. They develop daring ideas into life-saving and preventive medications by combining company innovation and commercial expertise, as well as insights from patients and partners. To continue to improve the development of medical equipment and digital health solutions, the firm makes long-term investments in novel treatments and technology, including curative stem cell-based therapies. ( refer: Novo Nordisk )

In March, Novo volunteers began testing samples for SARS-CoV-2 with RT-qPCR equipment in the ongoing coronavirus pandemic to increase available test capacity. In June, the business announced it would acquire AstraZeneca spin-off Corvidia Therapeutics for an initial sum of $725 million (up to a performance-related maximum of $2.1 billion), boosting its presence in cardiovascular diseases. In November, the company announced it would acquire Emisphere Technologies for $1.8 billion, gaining control of a pill-based treatment for diabetes. In December, Novo announced it would acquire Emisphere Technologies for $1.35 billion.

Country: Denmark
Market Cap Value: $187.83 Billion

Website: https://www.novonordisk.com/